Largest pharmaceutical companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 44 pharmaceutical companies in the United States ranked by net assets, at CZK 1.92T, ahead of Johnson & Johnson (CZK 1.81T) and Merck & Co (CZK 1.17T). Figures as of 20 Nov 2026, 06:46 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- PfizerCZK 1.92T
- Median
- CZK 14.5B
- Combined market value
- CZK 83.07T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | CZK 1.92T | CZK 3.49T | CZK 612.36 | 1.85% down | 15% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | CZK 1.81T | CZK 14.3T | CZK 5,939.94 | 2.04% down | 34% up | ||
| 3 | Merck & CoMRK · Health Care | CZK 1.17T | CZK 7.28T | CZK 2,953.07 | 3.61% down | 45% up | ||
| 4 | Abbott LaboratoriesABT · Health Care | CZK 1.16T | CZK 4T | CZK 2,309.58 | 0.58% down | 16% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | CZK 695B | CZK 2.12T | CZK 20,530.74 | 2.35% down | 28% up | ||
| 6 | Eli LillyLLY · Health Care | CZK 590B | CZK 26.76T | CZK 30,042.56 | 2.29% down | 33% up | ||
| 7 | Vertex PharmaceuticalsVRTX · Health Care | CZK 415B | CZK 2.94T | CZK 11,577.03 | 2.94% down | 27% up | ||
| 8 | Bristol-Myers SquibbBMY · Health Care | CZK 410.8B | CZK 2.65T | CZK 1,297.21 | 2.05% down | 30% up | ||
| 9 | ViatrisVTRS · Health Care | CZK 327.1B | CZK 506.8B | CZK 442.04 | 1.97% down | 99% up | ||
| 10 | Royalty PharmaRPRX · Health Care | CZK 216B | CZK 865.8B | CZK 1,505.77 | 1.38% down | 79% up | ||
| 11 | United TherapeuticsUTHR · Health Care | CZK 157.8B | CZK 529.5B | CZK 12,431.76 | 3.16% down | 22% up | ||
| 12 | Elanco Animal HealthELAN · Health Care | CZK 145.6B | CZK 292.2B | CZK 584.57 | 1.54% down | 26% up | ||
| 13 | BioMarin PharmaceuticalBMRN · Health Care | CZK 135.3B | CZK 264.5B | CZK 1,365.69 | 0.02% down | 17% up | ||
| 14 | ZoetisZTS · Health Care | CZK 74.1B | CZK 729.9B | CZK 1,796.39 | 5.59% down | 26% down | ||
| 15 | Ligand PharmaceuticalsLGND · Health Care | CZK 22.6B | CZK 127.6B | CZK 6,380.20 | 3.94% down | 50% up | ||
| 16 | Legend BiotechLEGN · Health Care | CZK 22.3B | CZK 69.4B | CZK 357.99 | 0.92% down | 41% down | ||
| 17 | Praxis Precision MedicinesPRAX · Health Care | CZK 19.5B | CZK 193.2B | CZK 6,912.95 | 1.87% up | 86% up | ||
| 18 | Alnylam PharmaceuticalsALNY · Health Care | CZK 17.5B | CZK 440.2B | CZK 3,286.82 | 1.06% down | 66% down | ||
| 19 | Belite BioBLTE · Health Care | CZK 17.1B | CZK 136.4B | CZK 3,357.97 | 3.33% down | 43% up | ||
| 20 | InsmedINSM · Health Care | CZK 16.4B | CZK 704.7B | CZK 3,212.11 | 20.58% up | 40% down | ||
| 21 | Spyre TherapeuticsSYRE · Health Care | CZK 15.9B | CZK 206.2B | CZK 2,170.83 | 3.77% down | 332% up | ||
| 22 | Summit TherapeuticsSMMT · Health Care | CZK 14.6B | CZK 188B | CZK 235.03 | 0.67% up | 36% down | ||
| 23 | TG TherapeuticsTGTX · Health Care | CZK 14.4B | CZK 218B | CZK 1,442.63 | 1.88% down | 117% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | CZK 14.4B | CZK 158.1B | CZK 1,444.85 | 4.15% down | 10% down | ||
| 25 | Cogent BiosciencesCOGT · Health Care | CZK 14.1B | CZK 107.3B | CZK 616.81 | 0.25% down | 20% down | ||
| 26 | Protagonist TherapeuticsPTGX · Health Care | CZK 13.7B | CZK 180B | CZK 2,757.62 | 2.47% down | 51% up | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | CZK 13.4B | CZK 204.9B | CZK 8,821.63 | 0.34% down | 27% down | ||
| 28 | Edgewise TherapeuticsEWTX · Health Care | CZK 11.6B | CZK 100.2B | CZK 915.43 | 0.48% down | 86% up | ||
| 29 | Dianthus TherapeuticsDNTH · Health Care | CZK 11B | CZK 106.2B | CZK 1,886.22 | 1.01% up | 108% up | ||
| 30 | Ionis PharmaceuticalsIONS · Health Care | CZK 10.9B | CZK 100.8B | CZK 605.24 | 0.62% down | 63% down | ||
| 31 | Oruka TherapeuticsORKA · Health Care | CZK 10.5B | CZK 147.1B | CZK 2,169.50 | 1.91% up | 255% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | CZK 10.4B | CZK 137.2B | CZK 970.57 | 1.25% up | 13% up | ||
| 33 | Definium TherapeuticsDFTX · Health Care | CZK 7.4B | CZK 89.7B | CZK 655.50 | 1.24% up | 168% up | ||
| 34 | ErascaERAS · Health Care | CZK 7.2B | CZK 111B | CZK 316.19 | 3.34% up | 395% up | ||
| 35 | Mirum PharmaceuticalsMIRM · Health Care | CZK 7B | CZK 138.6B | CZK 2,123.69 | 3.27% up | 34% up | ||
| 36 | Rhythm PharmaceuticalsRYTM · Health Care | CZK 3.1B | CZK 180.1B | CZK 2,597.08 | 1.88% down | 18% up | ||
| 37 | Travere TherapeuticsTVTX · Health Care | CZK 2.6B | CZK 103.1B | CZK 1,073.96 | 3.86% down | 45% up | ||
| 38 | Axsome TherapeuticsAXSM · Health Care | CZK 2B | CZK 158.7B | CZK 3,016.89 | 1.25% up | 6% down | ||
| 39 | Amneal PharmaceuticalsAMRX · Health Care | -CZK 1.6B | CZK 165.7B | CZK 475.61 | 2.24% down | 90% up | ||
| 40 | VeradermicsMANE · Health Care | -CZK 2.7B | CZK 116.7B | CZK 2,765.85 | 0.38% down | 231% up | ||
| 41 | PTC TherapeuticsPTCT · Health Care | -CZK 4.6B | CZK 108.3B | CZK 1,296.87 | 3.16% down | 21% down | ||
| 42 | CytokineticsCYTK · Health Care | -CZK 14.7B | CZK 159.4B | CZK 1,144.23 | 0.27% up | 19% down | ||
| 43 | BridgeBio PharmaBBIO · Health Care | -CZK 46.4B | CZK 338.6B | CZK 1,738.36 | 0.22% up | 21% up | ||
| 44 | AbbVieABBV · Health Care | -CZK 72.7B | CZK 11.14T | CZK 6,304.60 | 0.86% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2353 CZK).
Questions and answers
Which pharmaceutical companies in the United States rank first by net assets?
Pfizer (CZK 1.92T), Johnson & Johnson (CZK 1.81T) and Merck & Co (CZK 1.17T) are the top three of the 44 pharmaceutical companies in the United States ranked by net assets as of 20 Nov 2026, 06:46 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by net assets.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by net assets have a combined market value of CZK 83.07T as of 20 Nov 2026, 06:46 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.